Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

BACKGROUND AND AIM: Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therap...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JGH Open
Главные авторы: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Msasahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Формат: Artigo
Язык:Inglês
Опубликовано: Wiley Publishing Asia Pty Ltd 2020
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731817/
https://ncbi.nlm.nih.gov/pubmed/33319048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12408
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы